VITREORETINAL TECHNOLOGIES

vitreoretinal-technologies-logo

Vitreoretinal Technologies, Inc., an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.

#SimilarOrganizations #Financial #More

VITREORETINAL TECHNOLOGIES

Industry:
Biotechnology Health Care Therapeutics

Founded:
1999-01-01

Address:
Irvine, California, United States

Country:
United States

Total Employee:
1+

Status:
Active

Total Funding:
12 M USD


Similar Organizations

anthos-therapeutics-logo

Anthos Therapeutics

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.

genelabs-technologies-logo

Genelabs Technologies

Genelabs Technologies is a biopharmaceutical company engaged in the R&D of therapeutics for the treatment of infectious diseases.

Investors List

denovo-ventures_image

DeNovo Ventures

DeNovo Ventures investment in Series A - Vitreoretinal Technologies

More informations about "Vitreoretinal Technologies" on Search Engine